Navigation Links
Leaders in the Study of Allosteric Modulation to Discuss Latest Research at Allosteric and Orthosteric Modulator Congress

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Minneapolis, Minnesota (PRWEB) November 4, 2009 -- Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Our speakers will discuss key developments in the field, including the challenges facing researchers, the opportunities for pharma and recent successes in the field.

Allosteric modulators are on the cutting edge of small molecule drug discovery, and therefore, are generating a great deal of excitement among researchers. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Since orthosteric modulators need to compete with natural ligands, they require higher doses, raising safety issues. Allosteric modulators do not compete and may therefore be effective at lower, safer doses.

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress will highlight many key developments in the field. Conference attendees will come away with a better understanding of the following topics:

- Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders
- Dualsteric GPCR testing
- Allosteric modulation of GPCRs and transporters for the treatment of depression
- Structure-function approaches to understanding allosteric modulation of GPCRs
- Allosteric modulation of purine receptors
- Discovery of small molecule GPCR modulators
- Muscarinic receptors/GPCRs in endocrine and central nervous systems
- Morpheeins as a new pathway for allosteric drug discovery
- Allosteric proteins and the concept of allosteric modulators

Speakers at this year’s congress include:

- P. Jeffrey Conn, Ph.D., Director, Vanderbilt Program in Drug Discovery, Lee E. Limbird Professor of Pharmacology, Vanderbilt University Medical Center
- Patrick M. Sexton, Ph.D., Professor of Pharmacology, Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology, Monash University
- Jean-Pierre Changeux, Ph.D., Professor, Institut Pasteur
- Charlotte Keywood, MD, Chief Medical Officer, Addex Pharmaceuticals
- Connie Sanchez, Ph.D., Vice President Neuroscience, Lundbeck Research USA
- Prof. Dr. Klaus Mohr, Chairman, Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn
Kenneth A. Jacobson, Ph.D., Acting Chief, Laboratory of Bioorganic Chemistry, National Institutes of Health
Robert Lütjens, Ph.D., Head of Core Biology, Addex Pharmaceuticals
Marlene A. Jacobson, Ph.D., Senior Investigator, Merck Research Labs
Jurgen Wess, Ph.D., Chief, Molecular Signaling Section, National Institutes of Health, NIDDK

For more information about this conference, please visit or call 1-312-244-3703.

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Yakima Health Care Leader Tapped for Leadership Post at National Association
2. Tennessee Faith Leaders Call on Reps. Gordon & Blackburn to Co-sponsor Legislation to Protect Kids from Tobacco
3. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
4. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
5. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
6. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
7. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
8. CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans
9. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
10. Schooner Healthcare Services, LLC Announces New Leadership Team
11. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... discuss bioavailability and the need to integrate dose form selection in early phase ... OBN, the membership organization supporting and bringing together the UK’s emerging life sciences ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... and wellness consultation, has collaborated with Women’s Web – an online resource ... on topics on mental and emotional well-being relationship, life balance, stress, professional ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Finnleo, a ... Christmas Eve on several models of traditional and far-infrared saunas. , For ... Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European Grade ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed ... on behalf of a home health care worker who provided companionship services for the ... care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: